ATE517617T1 - Behandlung von parkinson erkrankung mit kape - Google Patents

Behandlung von parkinson erkrankung mit kape

Info

Publication number
ATE517617T1
ATE517617T1 AT02786994T AT02786994T ATE517617T1 AT E517617 T1 ATE517617 T1 AT E517617T1 AT 02786994 T AT02786994 T AT 02786994T AT 02786994 T AT02786994 T AT 02786994T AT E517617 T1 ATE517617 T1 AT E517617T1
Authority
AT
Austria
Prior art keywords
kape
parkinson
disease
treatment
neurodegenerative
Prior art date
Application number
AT02786994T
Other languages
English (en)
Inventor
Yansheng Du
Martin Farlow
Ruyu Du
Original Assignee
Yansheng Dr Du
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yansheng Dr Du filed Critical Yansheng Dr Du
Application granted granted Critical
Publication of ATE517617T1 publication Critical patent/ATE517617T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02786994T 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape ATE517617T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33921501P 2001-12-10 2001-12-10
PCT/US2002/039458 WO2003053425A1 (en) 2001-12-10 2002-12-10 Treatment of neurodegenerative and cardiovascular disorders

Publications (1)

Publication Number Publication Date
ATE517617T1 true ATE517617T1 (de) 2011-08-15

Family

ID=23328006

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02786994T ATE517617T1 (de) 2001-12-10 2002-12-10 Behandlung von parkinson erkrankung mit kape

Country Status (9)

Country Link
US (2) US20030139458A1 (de)
EP (1) EP1461025B1 (de)
JP (1) JP4511183B2 (de)
CN (1) CN100358515C (de)
AT (1) ATE517617T1 (de)
AU (1) AU2002351341A1 (de)
CA (1) CA2466928A1 (de)
TW (1) TWI335220B (de)
WO (1) WO2003053425A1 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070208087A1 (en) 2001-11-02 2007-09-06 Sanders Virginia J Compounds, compositions and methods for the treatment of inflammatory diseases
WO2003101927A1 (en) 2002-05-31 2003-12-11 Proteotech, Inc. Compounds, compositions and methods for the treatment of amyloid diseases and synucleinopathies such as alzheimer's disease, type 2 diabetes, and parkinson's disease
US20040167217A1 (en) * 2003-02-26 2004-08-26 Giovanni Scapagnini Neuroprotective effects of polyphenolic compounds
EP1988887A2 (de) * 2006-01-13 2008-11-12 University of South Carolina Verfahren und zusammensetzung zur behandlung von morbus parkinson
US8058309B2 (en) * 2006-12-04 2011-11-15 Novotyr Therapeutics Ltd. Protein kinase modulators and therapeutic uses thereof
CA2758016A1 (en) 2008-06-05 2009-12-10 Novotyr Therapeutics Ltd. Novel modulators of protein kinase signaling
CN101941907B (zh) * 2010-05-28 2015-04-01 毛腾淑 4-叔丁基苄基-3,4-二羟基肉桂酸酯及其用途和制备方法
EP2629766B1 (de) 2010-10-18 2017-02-22 Chemigen Kombinationstherapie
CN103384522B (zh) * 2010-11-15 2016-09-07 帕迪有限公司 咖啡酸衍生物和它们在改善神经细胞生存力中的用途
EP3021944B1 (de) 2013-07-14 2018-12-19 Yissum Research Development Company of the Hebrew University of Jerusalem, Ltd. Igf-1r signalweginhibitoren zur behandlung von neurodegenerativen erkrankungen
CN107250108B (zh) 2015-02-05 2020-11-27 特尔诺沃有限公司 用于治疗癌症的irs/stat3双重调节剂与抗癌剂的组合

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2721398A1 (de) * 1976-05-19 1977-12-01 Ciba Geigy Ag Alkylphenol-stabilisatoren
JPS62294634A (ja) * 1986-04-11 1987-12-22 ワ−ナ−−ランバ−ト・コンパニ− ジアリ−ルアルカノイドおよびその製法
US4959503A (en) * 1986-04-11 1990-09-25 Warner-Lambert Company Diarylalkanoids having activity as lipoxygenase inhibitors
JPH0678286B2 (ja) * 1988-03-18 1994-10-05 三井東圧化学株式会社 ジヒドロカフェイン酸誘導体およびそれを有効成分として含有する治療剤
DE3920616A1 (de) * 1989-06-23 1991-01-03 Boehringer Mannheim Gmbh Arzneimittel, enthaltend di-tert.-butylhydroxyphenyl-derivate sowie neue derivate
DE4126662A1 (de) * 1991-08-13 1993-02-18 Boehringer Mannheim Gmbh Neue 3,5-di-tert.butyl-4-hydroxyphenyl-derivate, verfahren zu ihrer herstellung und arzneimittel
AU1463997A (en) * 1995-12-22 1997-07-17 Acea Pharmaceuticals, Inc. Subtype-selective nmda receptor ligands and the use thereof
WO1998009620A1 (en) * 1996-09-05 1998-03-12 Research Development Foundation INHIBITION OF NUCLEAR TRANSCRIPTION FACTOR NF-λB BY CAFFEIC ACID PHENETHYL ESTER (CAPE), DERIVATIVES OF CAPE, CAPSAICIN (8-METHYL-N-VANILLYL-6-NONENAMIDE) AND RESINIFERATOXIN
TW466115B (en) * 1996-12-10 2001-12-01 American Home Prod Pharmaceutical composition of antioxidant from equilenin
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
GB9801398D0 (en) * 1998-01-22 1998-03-18 Anggard Erik E Chemical compounds
CN1212861C (zh) * 1999-09-17 2005-08-03 第一三得利制药株式会社 以NF－κB抑制剂为有效成分的心肌炎、扩张型心肌病和心衰的预防或治疗药

Also Published As

Publication number Publication date
JP4511183B2 (ja) 2010-07-28
EP1461025B1 (de) 2011-07-27
US8575215B2 (en) 2013-11-05
AU2002351341A1 (en) 2003-07-09
US20030139458A1 (en) 2003-07-24
WO2003053425A1 (en) 2003-07-03
US20100160433A1 (en) 2010-06-24
CN1589137A (zh) 2005-03-02
EP1461025A4 (de) 2009-07-29
JP2005513100A (ja) 2005-05-12
CN100358515C (zh) 2008-01-02
TW200301100A (en) 2003-07-01
EP1461025A1 (de) 2004-09-29
TWI335220B (en) 2011-01-01
CA2466928A1 (en) 2003-07-03

Similar Documents

Publication Publication Date Title
DE60218493D1 (de) Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
BR0309665A (pt) Tratamento de deficiência de alfa-galactosidase a
BR0016681B1 (pt) composição amaciante de tecidos, e, método de tratamento de tecido.
DE60033658D1 (de) Behandlung von prostata-krebs mit anti-erbb2 antikörpern
ATE410430T1 (de) 2,3-dihydro-6-nitroimidazoä2,1- büoxazolverbindungen zur behandlung von tuberkulose
BR0114054A (pt) Método para tratar alergias usando pirazóis substituìdos
ATE438630T1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
MXPA04005847A (es) Compuestos derivados de 4-sulfuro/sulfoxido/sulfonil-1h-pirazolilo, para uso en enfermedades asociadas con el receptor 5-ht2c.
ATE384699T1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
ATE254461T1 (de) Behandlung von augenschmerzen
MA27929A1 (fr) Utilisation de calcitonine pour le traitement de l'osteoarthrite
DE69925865D1 (de) 4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
ATE517617T1 (de) Behandlung von parkinson erkrankung mit kape
WO2001058476A3 (en) Methods and compositions for treatment of alzheimer's disease by enhancing plasmin or plasmin-like activity
DE60130365D1 (de) Die Verwendung von Rosiglitazon zur Behandlung von psychiatrischen Erkrankungen.
WO2004033423A3 (en) Anticancer compounds
WO2004026258A3 (en) Modulating vesicular monoamine transporter trafficking and function: a novel approach for the treatment of parkinson’s disease
DE50205466D1 (de) Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
DK1438034T3 (da) Anvendelse af -phenyl-3-dimethylaminiopropanforbindelser til behandling af urininkontinens
ATE464048T1 (de) Behandlung von alzheimer-krankheit und verwandten zuständen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
ATE317263T1 (de) Diphosphonat derivate von therapeutisch wirksamen stoffen
DE60201440D1 (de) Aryl-8-azabicyclo[3.2.1]octanes für die behandlung von depression

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties